CRISPR gene-editing treatment for sickle cell disease explained

Casgevy is the first FDA-approved medical treatment based on CRISPR gene-editing technology. Barely a decade after CRISPR gene-editing was discovered, the first medical treatment based on this revolutionary technology was approved by the U.S. Food and Drug Administration and now people with sickle cell disease, a painful, life-limiting, inherited blood disorder, have the potential for a cure.
www.umassmed.edu/news/news-ar...